NASDAQ$LUNG
Pulmonx Corporation · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Pulmonx's financial performance declined slightly in Q4 2020 due to the impact of the COVID-19 pandemic, but U.S. revenue increased.
Pulmonx Corporation reported a slight decline in worldwide revenue for Q4 2020, primarily due to the impact of the COVID-19 pandemic on international revenue. However, U.S. revenue saw an increase driven by expanded commercialization efforts. The company's gross profit and margin remained strong, but operating expenses increased due to investments in commercial and R&D functions.
- Total worldwide revenue in Q4 2020 was $9.8 million, a 5% decrease compared to Q4 2019.
- U.S. revenue increased by 4% to $4.9 million, driven by increased sales of the Zephyr Valve.
- International revenue decreased by 12% to $5.0 million due to the continued impact of the COVID-19 pandemic.
- Net loss in Q4 2020 was $9.3 million, or $0.27 per share, compared to a net loss of $4.7 million, or $2.48 per share, for the same period in 2019.
Headline financials
Revenue & EPS history
Pulmonx · Revenue · Quarterly
$9.83M
Forward guidance
Pulmonx expects revenue for the full year 2021 to range from $46 million to $50 million, representing approximately 41% to 53% growth over the company's full year 2020 revenue. Management expects revenue for the first quarter 2021 to range from $8.0 million to $8.3 million. Pulmonx expects total operating expenses for the full year 2021 to range from $85 million to $90 million inclusive of stock-based compensation.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
-3.4%
Avg return
Earnings day
-4.1%
Avg return
5 days after
-5.3%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+32.2%
Q4 2024
Best reaction
-64.7%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.5% | -6.7% | +12.6% | |
| Q4 2025 | +0.6% | -6.1% | -28.2% | |
| Q3 2025 | -18.9% | -28.6% | +29.1% | |
| Q1 2025 | -21.9% | -28.8% | -29.6% | |
| Q4 2024 | +32.2% | +30.7% | +17.0% | |
| Q3 2024 | -7.7% | +5.2% | -4.7% | |
| Q2 2024 | -8.1% | -15.4% | +3.7% | |
| Q1 2024 | +23.3% | +21.9% | -4.7% | |
| Q4 2023 | -17.7% | -27.9% | -36.1% | |
| Q3 2023 | +6.9% | +20.7% | +34.2% | |
| Q2 2023 | -4.1% | -8.0% | -26.0% | |
| Q1 2023 | +1.1% | -0.2% | -1.5% | |
| Q4 2022 | +20.8% | +26.0% | +27.1% | |
| Q3 2022 | -64.7% | -61.1% | -52.3% | |
| Q2 2022 | +9.2% | +19.9% | +5.7% | |
| Q1 2022 | +0.6% | -23.6% | -23.9% | |
| Q4 2021 | -6.9% | -2.5% | -12.5% | |
| Q3 2021 | +7.1% | +12.6% | -23.7% | |
| Q2 2020 | -7.6% | -10.9% | -1.6% | |
| Q2 2021 | +0.1% | +6.0% | +3.3% | |
| Q1 2020 | -5.8% | -5.3% | +9.9% | |
| Q1 2021 | -8.7% | -9.6% | -10.3% | |
| Q4 2020 | -4.1% | -3.4% | -20.2% | |
| Q3 2020 | -4.9% | -3.4% | +5.6% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro